Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

375.50GBp
19 Feb 2018
Change (% chg)

-- (--)
Prev Close
375.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,571,792
52-wk High
436.60
52-wk Low
246.50

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

Indivior bets on $1 billion anti-addiction shot as legal bill weighs

LONDON Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

15 Feb 2018

UPDATE 2-Indivior bets on $1 bln anti-addiction shot as legal bill weighs

LONDON, Feb 15 Britain's Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.

15 Feb 2018

Indivior legal costs rise, new anti-addiction drug ready

LONDON, Feb 15 Britain's Indivior, which makes drugs to treat opioid addiction and plans to launch a key new product this month, said on Thursday it had increased provisions for investigative and antitrust litigation matters to $438 million.

15 Feb 2018

BRIEF-Indivior Says FY 2017 ‍Net Revenue Increased 3% On Reported Basis

* FY 2017 ‍NET REVENUE AT $1,093M (FY 2016: $1,058M) INCREASED 3% ON A REPORTED BASIS (3% AT CONSTANT EXCHANGE)​

15 Feb 2018

BRIEF-Indivior Asserts New Patent Against ANDA-Filers

* U.S. UNIT FILED PATENT LAWSUITS AGAINST DR. REDDY'S, ACTAVIS, PAR, ALVOGEN AND TEVA FOR INFRINGEMENT OF UNITED STATES PATENT NO. 9,855,221

08 Feb 2018

BRIEF-Indivior Expects High Teens Effective Tax Rate For 2018​

* ‍EXPECTS ITS FUTURE US AFTER-TAX INCOME TO BE POSITIVELY IMPACTED BY RECENTLY-LEGISLATED CHANGES TO US CORPORATE TAXES​

01 Feb 2018

UK's Indivior replaces $484 mln in dollar, euro debt facilities

Dec 19 British drugmaker Indivior said it replaced all of its U.S. dollar and euro denominated outstanding term loans of about $484 million.

19 Dec 2017

BRIEF-‍Indivior Says Repricing And Maturity Extension Of Term Loan Facilities

* ‍INDIVIOR ANNOUNCES REPRICING AND MATURITY EXTENSION OF TERM LOAN FACILITIES AND REPLACEMENT OF CREDIT FACILITY​

19 Dec 2017

BRIEF-Indivior Announces NDA Acceptance Of RBP-7000 Risperidone Monthly Depot

* INDIVIOR ANNOUNCES NDA ACCEPTANCE OF RBP-7000 RISPERIDONE MONTHLY DEPOT

12 Dec 2017

U.S. FDA accepts application for Indivior's new schizophrenia drug

U.S. Food and Drug Administration (FDA) accepted Indivior's application for its new schizophrenia treatment, the British drugmaker said on Tuesday, boosting hopes of marketing the drug in the country.

12 Dec 2017

Earnings vs. Estimates